Indolent non-follicular non-Hodgkin lymphomas (INFL) are a heterogenous subset whose treatment has been poorly investigated. In this context we have evaluated the efficacy and safety of combined fludarabine and cyclophosphamide (FC) upfront therapy. Sixty-three patients with advanced INFL were enrolled in the study. Therapy consisted in FC combination (25 and 250 mg/m(2), i.v., respectively, for three consecutive days) every 28 days for six courses. After histological review, 61 patients (36 men, median age 64 years, range 40-70 years) were evaluated (22 small lymphocytic, 11 lymphoplasmacytic, 25 marginal zone and 3 CD5-negative non-Hodgkin lymphomas not otherwise specified). Further two patients were excluded for lack of essential data; six patients were withdrawn before the third cycle because of WHO grade III and IV toxicity. At the final evaluation, the overall response rate was 83% with 40.7% of complete remission. Intention-to-treat analysis showed that at the median follow-up of 36 months, overall survival, progression-free survival and failure-free survival were respectively 78%, 60% and 46%; remission duration among the 49 patients achieving complete remission/partial remission at the end of treatment was 65% (44-78) without significant differences between the main histotypes. The most frequent grade III and IV toxic events were haematological (neutropaenia 34%, anaemia 18% and thrombocytopaenia 11%) and infectious (10%). FC is effective for advanced untreated INFL. Early deaths and haematological toxicity suggest careful patient selection and monitoring.
|Data di pubblicazione:||2010|
|Titolo:||Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi.|
|Autore/i:||Ferrario, A.; Merli, F.; Luminari, Stefano; Stelitano, C.; Mannina, D.; Russo, M.; Mazza, P.; Marcheselli, Luigi; Goldaniga, M. C.; Federico, Massimo; Baldini, L.|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1007/s00277-010-1067-1|
|Codice identificativo ISI:||WOS:000286983200008|
|Codice identificativo Scopus:||2-s2.0-79951682605|
|Codice identificativo Pubmed:||20848104|
|Citazione:||Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi / Ferrario, A.; Merli, F.; Luminari, Stefano; Stelitano, C.; Mannina, D.; Russo, M.; Mazza, P.; Marcheselli, Luigi; Goldaniga, M. C.; Federico, Massimo; Baldini, L.. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - ELETTRONICO. - 90 (3)(2010), pp. 323-330.|
|Tipologia||Articolo su rivista|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris